Bayer, QIAGEN develop anti-cancer drug

Bayer, QIAGEN develop anti-cancer drug

5:43 AM, 26th October 2012
Bayer, QIAGEN develop anti-cancer drug

BERLIN, GERMANY: Bayer HealthCare has entered into a strategic partnership with QIAGEN Manchester Ltd for the development of molecular in vitro companion diagnostic tests. These tests shall be used to identify patients most likely to benefit from novel anti-cancer drug candidates developed by Bayer HealthCare.

Companion diagnostic tests aim to unlock molecular information from each patient’s tumour genome to guide treatment decisions with targeted medications for cancer and other diseases. This collaboration will support Bayer HealthCare’s oncological development programme and is part of Bayer HealthCare’s personalized medicine approach.

Qiagen will develop, manufacture and commercialize in vitro diagnostics (IVDs) as a companion diagnostic test for novel targeted anti-cancer therapies developed by Bayer HealthCare, which are currently in early development. The parties also agreed that over a period of five years they may initiate further development projects to develop molecular diagnostic tests in support of additional targeted therapies. Financial terms of the agreement were not disclosed.

“We are very pleased to be initiating these development programmes and our partnership with Bayer HealthCare. The collaboration combines Qiagen’s competencies in companion diagnostics with Bayer HealthCare’s drug development expertise in a joint effort to advance new targeted therapies for certain cancers that potentially help to reduce healthcare costs and - most importantly - advance the standard of care for patients,” said Dr Helge Lubenow, Senior Vice President, Molecular Diagnostics, Business Area and Member of the Executive Committee, QIAGEN.

© WOC News 

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


Evonik enters the roof-topping phase of hydrogen peroxide plant in China

ESSEN, GERMANY: Evonik Industries marked the roof-topping phase of construction for its hydrogen peroxide plant in Jilin, China, with a ceremony on 19 ...

Read more
Valspar to expand R&D centre in Minneapolis, US

MINNEAPOLIS, US: The Valspar Corporation plans to expand its research and development campus and renovate its former headquarters building, located in ...

Read more
Bayer scientists honoured with Otto Bayer Medal

LEVERKUSEN/COLOGNE, GERMANY: Scientists of the Bayer Group have been awarded the Otto Bayer Medal for their excellent achievements in three research p ...

Read more
BASF subsidiary Wintershall and Statoil agree on asset swap

LUDWIGSHAFEN, GERMANY: BASF group company, Wintershall is substantially expanding its production and reserves of oil and gas in the North Sea. Through ...

Read more
Dow builds EPDM plant in US Gulf Coast

MIDLAND, US: The Dow Chemical Company plans to build a new world-scale plant for the production of metallocene ethylene propylene diene monomer (EPDM) ...

Read more
Mitsui, Sumitomo cancel fertilizer business in Japan

TOKYO, JAPAN: Mitsui & Co Ltd and Sumitomo Corporation have been negotiating about the integration of their fertilizer business in Japan since the ...

Read more